Company: LCTX
Filing Date: 2025-11-12
Form Type: 424B3
Source: 0001193125-25-276229
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3) Registration No. 333-277758 PROSPECTUS SUPPLEMENT (To prospectus dated May 14, 2024 and prospectus supplement dated May 14, 2024) Up to $39,966,424 Common Shares This prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated May 14, 2024 (the “Prior Supplement”), which together with the accompanying prospectus dated May 14, 2024, contained in our Registration Statement on Form S-3 (Registration No. 333-277758) (the “Base Prospectus”), relating to the offer and sale of our common shares from time to time through or to B. Riley Securities, Inc. (“B. Riley”) pursuant to a Sales Agreement dated March 22, 2024 that we entered into with B. Riley. This prospectus supplement should be read in conjunction with the Prior Supplement and the Base Prospectus, including the documents incorporated by reference therein, and is qualified by reference to the Prior Supplement and the Base Prospectus, except to the extent that the information in this prospectus supplement supersedes the information in the Prior Supplement or the Base Prospectus. If there is any inconsistency between the information in the Prior Supplement and Base Prospectus, on the one hand, and this prospectus supplement, on the other, you should rely on the information in this prospectus supplement. Any information that is modified or superseded in the Prior Supplement or Base Prospectus shall not be deemed to constitute a part of the Prior Supplement or Base Prospectus, respectively, except as modified or superseded by this prospectus supplement. This prospectus supplement is not complete without, and may only be delivered or used in connection with, the Prior Supplement and the Base Prospectus, including any amendments or supplements thereto. Our common shares trade on the NYSE American and on the Tel Aviv Stock Exchange under the symbol “LCTX.” On November 10, 2025, the last reported sale price of our common shares on the NYSE American was $1.81 per share. Sales of our common shares, if any, under this prospectus supplement, the Prior Supplement and the Base Prospectus will be made by any method that is deemed an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”).